Levonorgestrel-Ethinyl Estradiol — Discount Pricing

Other medications in Women's Health

• Magnesium Sulfate
• Medroxyprogesterone Injection
• Methylergonovine
• Mifepristone
• Misoprostol Cervical
• Nifedipine (Tocolytic)
• Norethindrone-Ethinyl Estradiol
• Oxytocin

About Levonorgestrel-Ethinyl Estradiol

Levonorgestrel ethinyl estradiol is a widely prescribed combination oral contraceptive, primarily used to prevent pregnancy. As a member of TheDrugClub, you don't have to navigate the costs of this essential medication alone. We're dedicated to helping you access significant savings on your prescriptions, ensuring your health and financial well-being are prioritized.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Levonorgestrel-Ethinyl Estradiol is approved for (FDA label)

TYBLUME is indicated for use by females of reproductive potential to prevent pregnancy. TYBLUME (levonorgestrel and ethinyl estradiol tablets) is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Levonorgestrel-Ethinyl Estradiol (FDA label)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TYBLUME (levonorgestrel and ethinyl estradiol) tablets, are contraindicated in women who are over 35 years of age and smoke [ see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning . TYBLUME is contraindicated in women over 35 years old who smoke. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular side effects from combination hormonal contraceptive (CHC) use. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: b2482d51-d606-4aaa-8af4-19e4fe2f8872. SPL document ID: 5a0b1701-f165-fce7-e063-6294a90a8062. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Levonorgestrel-Ethinyl Estradiol (FDA label)

One pack of TYBLUME consists of 28 tablets: 21 active tablets are white, round, and debossed with 30 on one side and L2 on the other side. Each active tablet contains levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg. 7 inactive tablets (placebo) are peach-colored, round, and debossed with 1 on one side and L2 on the other side. A TYBLUME pack consists of 28 tablets: 21 white tablets (active), each containing levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg. 7 peach-colored tablets (inactive placebo).

Source: FDA prescribing information (DailyMed). Set ID: b2482d51-d606-4aaa-8af4-19e4fe2f8872. SPL document ID: 5a0b1701-f165-fce7-e063-6294a90a8062. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Levonorgestrel-Ethinyl Estradiol (FDA label)

The following serious adverse reactions with the use of CHCs are discussed elsewhere in labeling: Serious cardiovascular events [see Boxed Warning and Warnings and Precautions (5.1 and 5.4) ] Vascular events [see Warnings and Precautions (5.1) ] Liver disease [see Warnings and Precautions (5.2) ] Hypertension [see Warnings and Precautions (5.3) ] Gallbladder disease [see Warnings and Precautions (5.5) ] Adverse carbohydrate and lipid metabolic effects [see Warnings and Precautions (5.6) ] Headache [see Warnings and Precautions (5.7) ] Bleeding irregularities and amenorrhea [see Warnings and Precautions (5.8) ] Depression [see Warnings and Precautions (5.9) ] Cervical cancer [see Warnings and Precautions (5.10) ] Effect on binding globulins [see Warnings and Precautions (5.11) ] Hereditary angioedema [see Warnings and Precautions (5.12) ] Chloasma [see Warnings and Precautions (5.13) ] Risk of liver enzyme elevations with concomitant hepatitis C treatment [see Warnings and Precautions (5.14) ] The following adverse reactions associated with the use of oral CHCs were identified in clinical studies or postmarketing reports.

Source: FDA prescribing information (DailyMed). Set ID: b2482d51-d606-4aaa-8af4-19e4fe2f8872. SPL document ID: 5a0b1701-f165-fce7-e063-6294a90a8062. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Levonorgestrel-Ethinyl Estradiol (FDA label)

TYBLUME is contraindicated in females who are known to have the following conditions: A high risk of arterial or venous thrombotic diseases.

Source: FDA prescribing information (DailyMed). Set ID: b2482d51-d606-4aaa-8af4-19e4fe2f8872. SPL document ID: 5a0b1701-f165-fce7-e063-6294a90a8062. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Levonorgestrel-Ethinyl Estradiol (FDA label)

Vascular risks : Stop if a thrombotic or thromboembolic event occurs. Stop TYBLUME at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in females who are not breast-feeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years. ( 5.1 , 5.4 ) Liver disease : Discontinue TYBLUME if jaundice occurs. ( 5.2 ) Hypertension : If used in females with well-controlled hypertension, monitor blood pressure.

Source: FDA prescribing information (DailyMed). Set ID: b2482d51-d606-4aaa-8af4-19e4fe2f8872. SPL document ID: 5a0b1701-f165-fce7-e063-6294a90a8062. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Levonorgestrel-Ethinyl Estradiol (FDA label)

The sections below provide information on substances for which data on drug interactions with CHCs are available. There is little information available about the clinical effect of most drug interactions that may affect CHCs. However, based on the known pharmacokinetic effects of these drugs, clinical strategies to minimize any potential adverse effect on contraceptive effectiveness or safety are suggested. Consult the approved product labeling of all concurrently used drugs to obtain further information about interactions with CHCs or the potential for metabolic enzyme or transporter system alterations. No drug-drug interaction studies were conducted with TYBLUME. Enzyme inducers (e.g., CYP3A4) : May decrease the effectiveness of TYBLUME or increase breakthrough bleeding.

Source: FDA prescribing information (DailyMed). Set ID: b2482d51-d606-4aaa-8af4-19e4fe2f8872. SPL document ID: 5a0b1701-f165-fce7-e063-6294a90a8062. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.